概述
The Skin Repair Stack is a focused two-peptide protocol for accelerating skin healing, collagen production, and tissue recovery following damage from procedures, injuries, or chronic conditions. GHK-Cu is arguably the most well-validated peptide for dermatological applications. Its mechanisms in skin include: stimulation of collagen type I and III synthesis (the primary structural proteins of the dermis), promotion of glycosaminoglycan production (hyaluronic acid, dermatan sulfate) for hydration and plumpness, upregulation of integrin expression for cell adhesion and tissue organization, and attraction of macrophages for debris clearance and growth factor secretion. Clinical studies have demonstrated that GHK-Cu-containing products increase skin thickness, reduce fine lines, and improve elasticity within 12 weeks of consistent use. BPC-157 complements GHK-Cu through its unique vascular and growth factor effects. Skin healing requires robust blood supply for nutrient delivery and waste removal, and BPC-157''s documented promotion of angiogenesis (via VEGF upregulation) ensures adequate perfusion of healing tissue. It also modulates multiple growth factors simultaneously — EGF, FGF, and HGF — creating an environment that accelerates all phases of wound healing: inflammation, proliferation, and remodeling. Animal studies demonstrate that BPC-157 treated wounds show earlier collagen deposition, faster re-epithelialization, and improved tensile strength compared to controls. The combination is particularly effective for post-procedure recovery (after laser treatments, chemical peels, microneedling, or surgery), scar remodeling, chronic wound healing, and general skin rejuvenation in aging skin. GHK-Cu provides the building blocks and instructions for tissue reconstruction, while BPC-157 ensures the infrastructure (blood supply) and growth factor environment support rapid, high-quality repair. The beginner classification reflects the simplicity of the two-compound protocol, the extensive safety literature on both peptides, and the straightforward dosing schedule. Topical GHK-Cu can be applied directly to target areas for localized effects, while subcutaneous BPC-157 provides systemic support.
给药方案
500 mcg
每剂
250 mcg
每剂
目标与证据
警告
- BPC-157 was removed from the FDA Category 2 list (April 2026) but remains under PCAC review (July 23, 2026) — removal is not approval; not legal to compound yet.
Comments
Sign in to join the discussion
免责声明: 此堆栈由社区提交,仅供研究用途。Peptide Contacts不对提交的堆栈的安全性或有效性进行验证。使用任何肽类协议前,请务必咨询合格的医疗专业人员。